Orthogonal interleukin-2 receptor subunit beta

The orthogonal interleukin-2 receptor beta subunit is an **engineered mutant** of the natural interleukin-2 receptor beta (IL-2Rβ) chain designed to pair exclusively with a matched engineered interleukin-2 (orthoIL-2) ligand. This orthogonal pair enables highly selective stimulation of genetically modified T cells, such as those used in adoptive cell therapy for cancer, while avoiding activation of endogenous IL-2 pathways and minimizing systemic immune activation and toxicity. In contrast to the wild-type IL-2Rβ, the orthogonal variant contains specific mutations that prevent binding and signaling via native IL-2, ensuring that only cells engineered to express the orthogonal receptor variant will respond to the matched orthogonal cytokine[5]. This strategy enables precision targeting of cell therapies, improved safety, and reduced side effects but remains experimental and is not found in physiology or naturally occurring biology. - This target is **synthetic** and does not occur naturally in humans or other organisms. It is a product of protein engineering for selective cell therapy applications[5]. - While the natural interleukin-2 receptor beta subunit (IL2RB, also known as CD122) is a well-documented therapeutic target in immunology and oncology[1][2][3][4], the **orthogonal variant and its ligand are exclusively research or preclinical synthetic tools** and do not correspond to a canonical gene or protein found in nature. If you seek information about the wild-type, physiological target, see "Interleukin-2 receptor subunit beta" (IL2RB, CD122)[1][2][4].

Other names

Orthogonal IL-2 receptor betaOrtho IL-2RβorthoIL-2RβEngineered IL-2Rβ

Selective stimulation of engineered T cells expressing the orthogonal IL-2 receptor beta subunit via engineered orthogonal IL-2, without activating wild-type immune cells[5]